Central vision loss a problem following trabeculectomy?

Article

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision.

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision, according to the results of a study published in the August issue of Archives of Ophthalmology.

A retrospective review was conducted of the records of patients with severe preoperative visual field defects undergoing trabeculectomy between June 1998 and October 2005. Severe loss of central vision was defined as visual acuity (VA) of 20/200 or less in the affected eye, counting fingers or less if preoperative VA was less than 20/200, or a greater than four line reduction in Snellen VA.

Of 117 subjects, central vision loss occurred in seven (6%), due to hypotony maculopathy (three cases), uncontrolled elevated intraocular pressure (IOP) (two cases), posterior subcapsular cataract increase (one case) and inflammatory reaction (one case). A significant reduction in VA was noted following surgery, from -0.31 to -0.39 (logMAR, p=0.01). The patients who did suffer a severe loss of central vision, had significantly higher mean ±SD preoperative IOPs and higher rates of surgical complications compared with those who did not.

It would seem that there is a risk of severe central vision loss after trabeculectomy in patients with advanced visual field loss.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.